Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




May
27
Today In Oncology
Sonrotoclax Receives Accelerated Approval in Relapsed or Refractory MCL
Early Breast Cancer Is Surgery Omission Possible Following Estrogen and Ablative Radiation Therapy
Metastatic Castration-Resistant Prostate Cancer Addition of Olaparib to Radium-223
Outcomes in Patients With Breast Cancer and Obesity or T2D Receiving GLP-1 RAs
Long-Term EORTC Trial Challenges Assumptions About Lymph Node Radiation Therapy in Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo